| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDW641 |
| P698 | PubMed publication ID | 27993793 |
| P50 | author | Claus Garbe | Q32649750 |
| Michele Maio | Q37391116 | ||
| Ana Arance | Q42645931 | ||
| Grant McArthur | Q45893828 | ||
| Richard F. Kefford | Q46460242 | ||
| Christian U Blank | Q89370036 | ||
| P2093 | author name string | D Schadendorf | |
| A Hauschild | |||
| R Gonzalez | |||
| M Fluck | |||
| J Schachter | |||
| P Nathan | |||
| M Chamberlain | |||
| M-F Avril | |||
| K Margolin | |||
| S Robson | |||
| O Hamid | |||
| M Makrutzki | |||
| M Thebeau | |||
| P433 | issue | 3 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| metastatic melanoma | Q18975855 | ||
| P304 | page(s) | 634-641 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study | |
| P478 | volume | 28 |
| Q55206910 | An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. |
| Q91719232 | BRAF in the cross-hairs |
| Q52618225 | Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study |
| Q38844399 | Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update |
| Q91832432 | Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma |
| Q98226267 | Current State of Target Treatment in BRAF Mutated Melanoma |
| Q89811416 | Current approaches to the management of brain metastases |
| Q48109517 | Current chemotherapeutic regimens for brain metastases treatment |
| Q56673276 | Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter |
| Q47573654 | Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? |
| Q38775281 | Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. |
| Q88497994 | Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies |
| Q44470914 | Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis |
| Q90971217 | Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series |
| Q54950354 | Mechanisms and Therapy for Cancer Metastasis to the Brain. |
| Q58547833 | Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma |
| Q98467275 | Medical management of brain metastases |
| Q50125923 | Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges. |
| Q98467276 | Multidisciplinary patient-centered management of brain metastases and future directions |
| Q36175784 | Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report |
| Q92636859 | Oncogenic BRAF Alterations and Their Role in Brain Tumors |
| Q96953882 | Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations |
| Q58563207 | Pseudoprogression of Melanoma Brain Metastases |
| Q59341081 | Recent advances in managing brain metastasis |
| Q90080013 | Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside |
| Q38857040 | Targeted Therapies for Melanoma Brain Metastases |
| Q39192200 | Targeted Treatment of Brain Metastases |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q52673453 | The Evolving Landscape of Brain Metastasis. |
| Q92888273 | The Systemic Treatment of Melanoma |
| Q90474060 | The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q47105677 | The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy |
| Q98178296 | Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases |
| Q47899183 | Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? |
| Q52672321 | Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative |
Search more.